The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from PR Newswire

Questcor to Present at UBS Global Life Sciences Conference

Monday, September 20, 2010

Questcor to Present at UBS Global Life Sciences Conference06:30 EDT Monday, September 20, 2010UNION CITY, Calif., Sept. 20 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) announced today that it will present at the UBS Global Life Sciences Conference on Wednesday, September 22, 2010 at The Grand Hyatt Hotel in New York. Don M. Bailey, President and Chief Executive Officer, will discuss the Company's business strategy and historical financial performance at 3:30 p.m. Eastern Time.Attendance at this conference is by invitation only. A live audio and slides webcast of Questcor's presentation may be accessed through the Company's website at www.questcor.com. An archived replay of the presentation will be available after the live presentation, and can also be accessed at www.questcor.com. About QuestcorQuestcor Pharmaceuticals is a biopharmaceutical company whose products help patients with serious, difficult-to-treat medical conditions.  Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection). H.P. Acthar Gel ("Acthar") is an injectable drug that is approved for the treatment of certain disorders, including the treatment of exacerbations associated with multiple sclerosis ("MS") and to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that is due to lupus erythamatosus. In addition, Acthar is not indicated for, but is used in treating patients with infantile spasms ("IS"), a rare form of refractory childhood epilepsy, and opsoclonus myoclonus syndrome, a rare autoimmune-related childhood neurological disorder. For more information, please visit www.questcor.com.SOURCE Questcor Pharmaceuticals, Inc.For further information: Don Bailey of Questcor Pharmaceuticals, Inc., +1-510-400-0776, dbailey@Questcor.com; or Investors, Doug Sherk or Gregory Gin, both of EVC Group, Inc., +1-415-896-6818, or Media, Janine McCargo, +1-646-528-4034, all for Questcor Pharmaceuticals, Inc.